Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: Its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 8, 2014, Pages 1492-1496

  Basu, Sandip ^a   Sirohi, Bhawna ^a   Shrikhande, Shailesh V ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; DUAL TRACER IMAGING APPROACH; EDITORIAL; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HISTOPATHOLOGY; HUMAN; LABELING INDEX; MIB 1 INDEX; MOLECULAR IMAGING; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PERSONALIZED MEDICINE; RADIOISOTOPE THERAPY; RADIOLOGICAL PARAMETERS; TUMOR DIAGNOSIS; TUMOR PROLIFERATION INDEX; ADULT; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; GASTROINTESTINAL TUMOR; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING;

FLUORODEOXYGLUCOSE F 18; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; TECHNETIUM COMPLEX; TECHNETIUM TC 99M HYDRAZINONICOTINYL-TYR(3)-OCTREOTIDE;

ADULT; CELL PROLIFERATION; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOTECHNETIUM COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84905572433     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2805-8     Document Type: Editorial

References (20)

1. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. Barcelona consensus conference participants. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157-76.
2. Öberg K, Knigge U, Kwekkeboom D, Perren A; ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23 Suppl 7:vii124-30.
3. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707-12.
4. Klimstra DS, Modlin IM, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34:300-13.
5. Klöppel G, Couvelard A, Perren A, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90:162-6.
6. Rindi G, Kloppel G, Alhman H, et al. TNMstaging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395Y401.
7. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757Y762.
8. Travis WD. The concept of pulmonary neuroendocrine tumours. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004:19Y20.
9. Shrikhande SV, Sirohi B, Goel M, Barreto SG. Pancreatic neuroendocrine tumors. Indian J Gastroenterol. 2013;32(1):3-17.
10. Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, O'Dorisio MS, O'Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16 (erratum: 41(3):584)
11. Basu S, Kand P, Mallia M, Korde A, Shimpi H. Gratifying clinical experience with indigeneously formulated single vial lyophilized HYNIC-TOC kit at the radiopharmaceutical division of BARC: a pivotal boost for building up a peptide receptor radionuclide therapy programme in an Indian setting. Eur J Nucl Med Mol Imaging. 2013;40(10):1622-4.
12. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer. 2010;102:1106-12.
13. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10 Suppl 2:S23-9. (Pubitemid 29288527)
14. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudła B, de Herder WW, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220-6.
15. Kwee TC, Basu S, Saboury B, Ambrosini V, Torigian DA, Alavi A. A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging. 2011;38(6):1158-70.
16. Basu S, Kumar R, Rubello D, Fanti S, Alavi A. PET imaging in neuroendocrine tumors: current status and future prospects. Minerva Endocrinol. 2008;33(3):257-75.
17. Basu S, Kwee TC, Gatenby R, Saboury B, Torigian DA, Alavi A. Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging. 2011;38(6):987-91.
18. Basu S. Should grade of tracer uptake on somatostatin receptor-targeted imaging be the major determinant and break the barrier of histopathologic criteria for determining the suitability of peptide receptor radionuclide therapy? J Nucl Med. 2013;54(11):2018-9.
19. 177Luoctreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(5):925-33.
20. Campana D, Capurso G, Partelli S, Nori F, Panzuto F, Tamburrino D, et al. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging. 2013;40(8):1197-205.